alphamab oncology-j9九游会老哥俱乐部

english j9九游会老哥俱乐部中文繁体

english j9九游会老哥俱乐部中文繁体

alphamab oncology reports full year 2024 financial results and business highlights

full year 2024 financial results and business highlights, reached profitability for the first time on an annual basis
anti-her2 biparatopic adc jskn003 has been granted breakthrough-therapy designation for the treatment of proc

not restricted to her2 expression levels
alphamab oncology announces the first patient dosed in a phase iii clinical study for ovarian cancer of anti-her2 bispecific adc jskn003

the study aims to compare the efficacy and safety of jskn003 versus investigator-selected chemotherapy in this patient population

vision, mission and core values

our mission : to make cancer manageable and curable

our vision : to develop differentiated, clinically valuable and globally competitive new drugs

our core values : innovation, ownership, integrity, quality, growth

learn more

proprietary platforms
innovative pipeline
biologics manufacturing

world-class bispecific, adc and mix-mab platforms

in complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. alphamab oncology has developed several proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

learn more

innovative pipeline with significant potential and mitigated development risk

leveraging its proprietary technology platforms, alphamab oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

learn more

state of art cgmp manufacturing with a solid track record

the production of biologics, such as antibody drugs, is a complex, lengthy and costly process. we have established our own cgmp production facilities with strong in house expertise to address the manufacturing issues.

learn more